This is the latest and most up-to-date Toxicity Screening Market Analysis Report from Select Biosciences. This comprehensive report provides a qualitative and quantitative analysis of the toxicity screening space, market metrics, and thorough bottom-up based market trends obtained via detailed market surveys administered by Select Biosciences to a worldwide industry participant pool.
The report features perspectives from the pharmaceutical industry participants engaged in toxicity screening providing a framework to understand the latest industry trends in toxicity screening, the challenges, and the emerging trends. This report is important to the industry as it combines commercial/market analysis, regulatory trends in toxicity screening, as well as the technical details of various screens, emerging classes of biomarkers, and covers the all-important category of cardiotoxicity and LQTS-inducing liability of compounds.
|
- Chapter I. Executive Overview of the Space
- Scope of this Report
- Market Definitions
- Market Segmentation
- Market Sizing
- Chapter II. Toxicity Screening in Drug Discovery: Current Trends and Emerging Themes in the Marketplace
- The Process of Drug Metabolism
- Various Biological Assay Systems for ADME and Toxicity Screening
- Bottom-up Market Survey of Worldwide Industry Participants: Qualitative and Quantitative Market Analysis
- Chapter III. hERG, LQTS, Torsades de Pointes
- Drug-induced long QT syndrome (LQTS): Focus on hERG
- Why does hERG get blocked so easily?
- How widespread is hERG inhibition in the pharmaceutical industry
- Drug-acquired LQTS: Description of some high-profile drugs that affect hERG
- Analysis of the hERG marketplace
- Regulatory Section: ICH S7B and E14 guidelines
- Chapter IV. Toxicity Screening Industry Landscape: Perspectives from the Pharmaceutical Industry
- Genentech, Inc.
- Merck
- Abbott
- GlaxoSmithKline
- Eli-Lilly & Co.
- AstraZeneca
- Celgene Corporation
- Bristol-Myers Squibb
- Chapter V. Developing Drugs with Safety Signals: Industry Perspectives
- University of Maryland
- Pfizer
- US FDA
- Chapter VI. Toxicity Industry Landscape: Perspectives from Regulatory Agencies
- US FDA
- Health Canada
- Appendix I. Research Methodology
- Appendix II. hERG: Technology and Business
- Supporting Technical and Regulatory Trends Analysis
- Appendix III. Preclinical and Clinical non-QT Testing: Industry
- Perspectives
- Appendix IV. Cardiotoxicity and Troponins: Industry Perspectives
Share this report
Other tasks Related Markets Manufacturing, Packaging & Detailing Reports Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|
